MedTrace Logo

Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

NCT00250926 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2016-04-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if the combination of bortezomib (Velcade), dexamethasone (Decadron) and rituximab (Rituxan) is effective in treating Waldenstrom's macroglobulinemia.

Conditions

  • Waldenstrom's Macroglobulinemia

Interventions

DRUG

Bortezomib

Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles

DRUG

Dexamethasone

Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles

DRUG

Rituximab

Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles

Sponsors & Collaborators

Principal Investigators

  • Steven P. Treon, MD, MA, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-03-31
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00250926 on ClinicalTrials.gov